Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
178 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03286634 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | active not recruiting | Phase 2 | 60 | National Hospital Organization Nagoya Medical CenterOTHER | 6 | May 11, 2026 | clinicaltrials |
| NCT04665843 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck(SKYSCRAPER-09) | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY |
| 13 |
| May 5, 2026 |
| clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT06864169 | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)(REJOICE-GI01) | active not recruiting | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 23, 2026 | clinicaltrials |
| NCT05635708 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 400 | BeiGeneINDUSTRY | 15 | Apr 15, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | terminated | Phase 2 | 211 | Agenus Inc.INDUSTRY | 7 | Mar 27, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | suspended | Phase 2 / Phase 3 | 150 | Mirror Biologics, Inc.INDUSTRY | 2 | Oct 23, 2025 | clinicaltrials |
| NCT03822468 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer(AMALEE) | completed | Phase 2 | 376 | Novartis PharmaceuticalsINDUSTRY | 23 | Oct 16, 2025 | clinicaltrials |
| NCT05564052 | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma(VEGA) | completed | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 7, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT04027647 | Phase 2 Study of Dacomitinib in NSCLC | active not recruiting | Phase 2 | 118 | National Cancer Centre, SingaporeOTHER | 5 | Jun 12, 2025 | clinicaltrials |
| NCT05394831 | A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | recruiting | Phase 1 / Phase 2 | 150 | J Ints BioINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04732494 | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(AdvanTIG-203) | completed | Phase 2 | 125 | BeiGeneINDUSTRY | 6 | Jan 31, 2025 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT02057380 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | completed | Phase 2 | 13 | Astellas Pharma Global Development, Inc.INDUSTRY | 7 | Nov 20, 2024 | clinicaltrials |
| NCT06525870 | Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial(Trichlosil) | unknown | Phase 2 | 44 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03839823 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer(RIGHT Choice) | completed | Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 13 | Oct 9, 2024 | clinicaltrials |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | terminated | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 9, 2024 | clinicaltrials |
| NCT01737827 | Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 24, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT04677504 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | completed | Phase 2 | 162 | Hoffmann-La RocheINDUSTRY | 13 | Jul 3, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | completed | Phase 1 / Phase 2 | 34 | The Thai Lymphoma Study GroupOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 27 | Mahidol UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03694522 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer(FIGHT) | completed | Phase 2 | 155 | Five Prime Therapeutics, Inc.INDUSTRY | 18 | Feb 28, 2024 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT04208334 | The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer(CurChexia) | completed | Phase 2 | 20 | Phramongkutklao College of Medicine and HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT05037539 | Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain | completed | Phase 1 / Phase 2 | 20 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT05366062 | ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | unknown | Phase 2 | 28 | Epitopoietic Research CorporationINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials